Didn't expect news to come from the Janssen direction. Cool.
Monday February 14, 8:30 am Eastern Time
Company Press Release
SOURCE: Gliatech Inc.
Need for Anti-Inflammatory Therapy in Alzheimer's
Disease Identified by Gliatech Scientists
Article Published in Neurobiology of Aging
CLEVELAND, Feb. 14 /PRNewswire/ -- Gliatech Inc. (Nasdaq: GLIA - news) announced today that an article in the
February 14 issue of Neurobiology of Aging, authored by company scientists, reveals that an established mouse model of
Alzheimer's disease (AD) shows brain inflammation that is similar to that observed in AD patients.
The AD brain is characterized by the presence of amyloid plaques, and these plaques can trigger glial cell activation which leads
to an inflammatory response in the brain. Presently, AD research has been greatly aided by the development of transgenic mice
strains that form amyloid plaques. However, it has been unclear whether these mice have the plaque-associated inflammation
seen in AD.
Gliatech scientists examined the brains of one of the AD transgenic mice strains for evidence of glial-mediated inflammation.
This strain of mice is recognized for their age-dependent development of AD-like plaques. Company researchers found within
these mice a close association between amyloid fibril-containing plaques and activated glial cells that expressed cytokines such
as tumor necrosis factor alpha, interleukin-1 and interleukin-6. These cytokines can result in an inflammatory response in the
brain.
This is the first reported demonstration of a plaque-associated inflammatory response in an AD transgenic mouse model, and
further validates the Company's position that amyloid fibrils trigger glial cell activation that contributes to disease progression.
Gliatech has been an industry leader in the area of inflammation in AD.
Gliatech is a leader in the discovery and development of therapeutic products based on the properties of glial cells. The
Company applies its core glial research to developing innovative products for major unmet human health care needs. Current
development initiatives are targeting products to improve surgical outcomes and to treat neurological disorders.
Certain statements in this press release constitute ''forward-looking statements'' that are subject to risks and uncertainties which
may cause the actual results of the Company to be different from expectations expressed or implied by such forward-looking
statements. Such factors include, but are not limited to, uncertainty of market acceptance of the Company's products, the
uncertainty of the continued development of monoclonal antibodies and other risk factors detailed in the Company's SEC
filings.
SOURCE: Gliatech Inc. |
